Centene Corporation is expected to report Q2 2026 revenue of $47.53 billion and earnings per share of $0.89, with its current price of $63.35 trading slightly below the average analyst price target of $64.61.
Investors are primarily focused on the Medicaid Health Benefits Ratio (HBR), which serves as the primary indicator for medical cost management and overall margin stability.
Recent negative read-through from peer Molina Healthcare has heightened concerns regarding Marketplace margin deterioration and elevated medical care costs across the sector. Despite these industry headwinds, analysts are watching for stabilization in Medicaid membership and the impact of recent state contract wins to support the company’s full-year outlook.